Abstract
Introduction: Obesity is a serious, worldwide and growing problem, with associated complications ranging from cardiovascular disease to cancer. It has been suggested that a subgroup of obese patients- the “metabolically healthy” (MH)- would constitute a phenotype whose cardiovascular risk would be closer to that of normal weight individuals and lower than that of obese patients with other risk factors. The definitions of MH obesity are heterogeneous, what makes the estimation of its prevalence quite difficult. Besides that, data are still controversial about the risk of incident cardiovascular disease in these patients and therefore this remains an unresolved matter. In parallel, the possibly lower risk of MH obesity may raise questions about the need for weight loss in MH obese patients.
Conclusion: This issue should be carefully addressed, and evidence for a “benign” profile of MH obesity critically evaluated, as obesity is a risk factor for numerous health outcomes, and weight loss in obese people additionally offers protection against these nonmetabolic diseases.
Keywords: Obesity, metabolic syndrome, cardiovascular disease, prognosis, diabetes, healthy.
Current Diabetes Reviews
Title:“Metabolically Healthy” Obesity: Fact or Threat?
Volume: 14 Issue: 5
Author(s): Andrea De Lorenzo*, Cristiane da Cruz Lamas, Rafael Lessa and Annie Seixas Bello Moreira
Affiliation:
- Instituto Nacional de Cardiologia, Rua das Laranjeiras 374, Rio de Janeiro, RJ,Brazil
Keywords: Obesity, metabolic syndrome, cardiovascular disease, prognosis, diabetes, healthy.
Abstract: Introduction: Obesity is a serious, worldwide and growing problem, with associated complications ranging from cardiovascular disease to cancer. It has been suggested that a subgroup of obese patients- the “metabolically healthy” (MH)- would constitute a phenotype whose cardiovascular risk would be closer to that of normal weight individuals and lower than that of obese patients with other risk factors. The definitions of MH obesity are heterogeneous, what makes the estimation of its prevalence quite difficult. Besides that, data are still controversial about the risk of incident cardiovascular disease in these patients and therefore this remains an unresolved matter. In parallel, the possibly lower risk of MH obesity may raise questions about the need for weight loss in MH obese patients.
Conclusion: This issue should be carefully addressed, and evidence for a “benign” profile of MH obesity critically evaluated, as obesity is a risk factor for numerous health outcomes, and weight loss in obese people additionally offers protection against these nonmetabolic diseases.
Export Options
About this article
Cite this article as:
De Lorenzo Andrea*, da Cruz Lamas Cristiane, Lessa Rafael and Moreira Seixas Bello Annie , “Metabolically Healthy” Obesity: Fact or Threat?, Current Diabetes Reviews 2018; 14 (5) . https://dx.doi.org/10.2174/1573399813666170502105859
DOI https://dx.doi.org/10.2174/1573399813666170502105859 |
Print ISSN 1573-3998 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6417 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Neurodegenerative Diseases of the Retina and Potential for Protection and Recovery
Current Neuropharmacology Role of Vascular Endothelial Growth Factor in Kidney Disease
Current Vascular Pharmacology Cardiac Role of the Transcription Factor NF-κB
Cardiovascular & Hematological Disorders-Drug Targets Research Advancements in Porcine Derived Mesenchymal Stem Cells
Current Stem Cell Research & Therapy Potential Application of 5-Aryl-Substituted 2-Aminobenzamide Type of HDAC1/2- Selective Inhibitors to Pharmaceuticals
Current Pharmaceutical Design Clopidogrel and Aspirin in Cardiovascular Medicine: Responders or Not -- Current Best Available Evidence
Cardiovascular & Hematological Agents in Medicinal Chemistry The Role of PPARs in Pathological Cardiac Hypertrophy and Heart Failure
Current Pharmaceutical Design Hypertension and Angiogenesis
Current Pharmaceutical Design Anti-Atherosclerotic Therapy Based on Botanicals
Recent Patents on Cardiovascular Drug Discovery Cardioprotective Potential of Iron Chelators and Prochelators
Current Medicinal Chemistry Impact of Omega-3 and Trans Fatty Acids on Vascular Remodeling:Opposing Roles in Cardiovascular Health
Current Enzyme Inhibition Evaluation of Anticancer, Antibacterial and Antioxidant Properties of a Medicinally Treasured Fern Tectaria coadunata with its Phytoconstituents Analysis by HR-LCMS
Anti-Cancer Agents in Medicinal Chemistry Modulation of Cardiovascular Remodeling with Statins: Fact or Fiction?
Current Vascular Pharmacology Mechanisms Involved in the Genesis of Diabetic Nephropathy
Current Diabetes Reviews Antiplatelet Therapies: Aspirin at the Heart of New Directions
Cardiovascular & Hematological Disorders-Drug Targets Ivabradine: a Selective If Current Inhibitor in the Treatment of Stable Angina
Recent Patents on Cardiovascular Drug Discovery Annexin A5 Imaging: An Academic Research – Clinical Trials and Theses
Current Molecular Imaging (Discontinued) Exercise as Treatment for Neuropathy in the Setting of Diabetes and Prediabetic Metabolic Syndrome: A Review of Animal Models and Human Trials
Current Diabetes Reviews Facilitated/Pharmaco-invasive Approaches in STEMI
Current Cardiology Reviews Interaction of Carbon Monoxide with Transition Metals: Evolutionary Insights into Drug Target Discovery
Current Drug Targets